After an initial exposure, patients can develop test-taking/learning strategies called the "test sophistication effect." Patients with cirrhosis with prior overt hepatic encephalopathy (OHE) could have persistent learning impairments. The aim was to define learning/test sophistication on EncephalApp (downloadable application) in OHE patients compared with patients without prior overt hepatic encephalopathy (no-OHE) patients and controls cross-sectionally and longitudinally. The EncephalApp Stroop App consists of 2 sections: the easier "Off" run assesses psychomotor speed while the difficult "On" run assesses cognitive flexibility. For the cross-sectional analysis, outpatients with cirrhosis with/without controlled OHE and healthy controls underwent EncephalApp testing, which requires 5 Off and 5 On runs. We studied the difference in time required between completing trial 1 compared with trial 5 (delta 1-5) in both the On and Off runs in controls, all patients with cirrhosis, and between prior OHE/no-OHE patients with cirrhosis. For the longitudinal analyses, 2 groups of patients with cirrhosis were studied; 1 was administered the EncephalApp 2 weeks apart, and the second was administered before and 6 months after liver transplantation. The study included 89 controls and 230 patients with cirrhosis (85 prior OHE; Model for End-Stage Liver Disease, 11) with similar age (64 versus 61 years; P 5 0.92). Patients with cirrhosis had impaired EncephalApp total times and impaired learning on the On runs compared with controls. OHE patients had worse EncephalApp times and learning with the On runs compared with no-OHE patients, which persisted in the longitudinal cohort. No differences in learning were seen in the Off runs. After transplant, there was restoration of learning capability with the On runs in the OHE patients. In conclusion, cognitive flexibility tested by the EncephalApp On runs improves over time in healthy controls and no-OHE but not prior OHE. Psychomotor speed remains similar over time. The learning impairment manifested by patients with cirrhosis with OHE is restored after transplant.
Patients with hepatic encephalopathy (HE) have impaired daily functioning, which limits their independence.
(1) HE forms a spectrum of cognitive alterations divided into covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE). (2) These deficits in working memory, response inhibition, and psychomotor speed are associated with psychosocial impairments. (3) In OHE, there is experimental, autopsy, and clinical evidence of persistent cognitive impairment related to learning by using tests of response inhibition (inhibitory control test [ICT] ) as well as on the psychometric hepatic encephalopathy score (PHES) in a limited number of patients. (4) (5) (6) (7) (8) This persistent cognitive impairment is observed despite standard of care therapy and normal mentation, and it could further worsen the ability of these patients to function independently.
The EncephalApp Stroop, which is based on the original Stroop effect, has been validated to define Abbreviations: CHE, covert hepatic encephalopathy; HE, hepatic encephalopathy; ICT, inhibitory control test; LT, liver transplantation; no-OHE, patients without prior overt hepatic encephalopathy; OHE, overt hepatic encephalopathy; PHES, psychometric hepatic encephalopathy score.
cognitive impairment in cirrhosis. (9) (10) (11) It consists of 5 separate runs of an easier "Off" state that evaluates psychomotor speed and 5 runs of the more difficult "On" state that assesses cognitive flexibility, inhibition of a dominant response, and dealing with interference. (12) In the Off runs, the patient is required to identify as quickly as possible the color of ink used to create the hashtag. Therefore, these trials specifically assess psychomotor speed. In contrast, in the On runs the patient sees a word written in a discordant ink color. For example, patients are asked to disregard reading the written word, but instead select their response based on the color of ink used to spell the word. The brain easily understands the meaning of words as a result of habitual reading. Color recognition is not an automatic process. Therefore, cognitive interference occurs when the word reading and color naming pathways are activated simultaneously. In the On trial run, the pathway (color recognition) that leads to the response (identify ink color, not the written word) is the weaker of the 2 pathways. (13) Therefore, like the Off trial, the On trial has a psychomotor speed component, but it uniquely demands response inhibition and cognitive flexibility. Brain imaging techniques have shown 2 main brain regions involved in performing the Stroop task. The anterior cingulate cortex allows for the allocation of attentional resources and the selection of an appropriate response. The dorsolateral prefrontal cortex creates the appropriate rules for the brain to accomplish response inhibition. (14, 15) These cognitive functions are critical for daily function, and their course after development of OHE and after transplant need further elucidation. Studies evaluating learning associated with test familiarity have shown that the magnitude of carryover effects associated with test familiarity is related to the disorder being assessed. (16, 17) For example, in 1 study, (18) the extent of practice effects was associated with an individual's level of intelligence. Those with higher IQ scores at baseline testing showed greater improvement with subsequent test administrations. It may be the case that cirrhotic patients with a prior history of OHE will suffer specific neuropathologic changes that serve to reduce brain reserve, making them less able to benefit from test familiarity. Although the current study is not designed to clarify neuropathologic processes associated with learning deficits in patients with cirrhosis, a recent study using measures of functional brain activation (19) demonstrated alteration in cortical structures necessary for good performance on the EncephalApp task (ie, frontal/parietal regions). In a multicenter study (20) examining cognitive function in children following liver transplantation (LT), children who had received LT prior to 5 years of age displayed twice the rate of intellectual delay and 3 times the rate of learning disability compared with the general population. Most clinicians believe that the majority of the clinical features recognized as HE are reversed by successful LT. (21) However, Campagna et al. found an incomplete reversal of certain cognitive defects in patients who had bouts of overt HE before they underwent LT. Interestingly, although abnormal electroencephalogram patterns normalized after transplantation, previously abnormal cognition domains did not return to expected baseline in patients with a pretransplant history of overt HE. (22) We hypothesized that both psychomotor speed and cognitive flexibility will be impaired in patients with prior OHE on maximal treatment tested by the improvement in the fifth run compared with the first run on the "On" and "Off" states of EncephalApp compared with patients without OHE and healthy controls.
Patients and Methods

STUDY POPULATION
We prospectively enrolled patients with cirrhosis of all etiologies from our outpatient clinics. Cirrhosis was diagnosed using liver biopsy, FibroScan, radiological evidence of cirrhosis, endoscopic evidence of varices in patients with chronic liver disease, or evidence of frank decompensation. All patients required a Mini Mental status examination of >25 to qualify for the study. Data recorded were years of education (high school equivalent was 12 years), demographics, and cirrhosis complications including OHE and treatment. Patients were excluded if they were actively using psychotropic drugs or were actively abusing psychoactive substances including alcohol, were color-blind, or were unable to understand English. Patients with a history of OHE were on standard of care with lactulose and/or rifaximin and were adherent on these medications based on active questioning, chart review, and pharmacy dispensing records. None of the patients without prior OHE were on lactulose or rifaximin. We enrolled agematched healthy controls without any chronic diseases as well. Two additional patient groups were recruited for longitudinal studies; 1 group was tested at least 2 weeks apart with EncephalApp and another group was tested before and 6 months after LT.
ENCEPHALAPP TESTING
Potential patients who were comfortable with the tablet or smartphone and were not color-blind were tested based on the EncephalApp Stroop test by a trained provider. After appropriate instructions and a trial run, patients were tested on the application. A total of 5 runs were done in the Off state and then 5 more runs were attempted on the On state. Total stage times were recorded for all groups. Standard EncephalApp metrics are the times taken for 5 successful Off stage runs (OffTime), for 5 successful On stage runs (OnTime), total time taken (OffTime 1 OnTime), extra time in the On stage (OnTime -OffTime), and number of runs needed to complete 5 Off and 5 On runs successfully. Learning was defined by the change in times from run 1 to run 5 compared between groups (Fig. 1) . CHE was assessed based on US norms from the a multicenter North American experience (23) now available online. (24) STATISTICAL ANALYSIS
Statistical analysis was performed using t tests, Wilcoxon rank tests, and chi-square tests as appropriate for patients. Variables compared were etiology of cirrhosis, demographics, years of schooling and education level, cirrhosis severity, and median run times on the Off and On states. Patients tested twice were analyzed by using paired t tests or Wilcoxon paired rank sum tests. The study was conducted at the Virginia Commonwealth University and McGuire VA Center in Richmond, VA, and the study protocol was approved by the institutional review boards at both centers.
Results
DEMOGRAPHICS AND DISEASE DETAILS
We enrolled a total of 230 patients with cirrhosis and 89 controls for the cross-sectional study. The controls had similar age (59.1 6 9.9 versus 60.5 6 8.3 years; P 5 0.26) and education status (14.8 6 2.6 versus 14.0 6 2.4 years; P 5 0.07) but a lower proportion of men (52 versus 67; P < 0.001) compared with the patients with cirrhosis. Of the enrolled patients with cirrhosis, 145 had never had any documented OHE episodes and were not on any therapy. The remaining 85 patients with cirrhosis had 1 or more episodes of OHE before enrollment and were alert and oriented at enrollment. Of the 85 OHE patients, 23 had their last episode within 6 months, 22 had it between 6 months and 1 year, whereas 40 patients had experienced OHE more than 1 year ago. A total of 15 patients were on lactulose only, 47 were on lactulose and rifaximin, whereas 23 patients were not on regular OHE treatment. OHE patients had similar demographics compared with patients without prior overt hepatic encephalopathy (no-OHE) but were significantly more likely to have alcoholic disease and Model for EndStage Liver Disease (MELD) score and a lower prevalence of hepatitis C (Table 1) . 
CROSS-SECTIONAL STANDARD ENCEPHALAPP METRICS
All standard metrics were higher (more impaired) in patients with cirrhosis compared with controls and within cirrhosis was significantly higher in those with prior OHE (Tables 1 and 2 ). There was no difference in the number of runs required between the controls and patients with cirrhosis whereas in OHE patients, there was a higher number of runs required in the On stage. As expected, age was correlated with EncephalApp Off and On times (r 5 0.4; P < 0.001 for both) as was MELD score (OffTime, r 5 0.2, P 5 0.02; OnTime, r 5 0.2, P 5 0.03) and education (r 5 -0.2; P 5 0.02 for both). Within the cirrhosis group, no significant differences were found between alcohol/ nonalcoholic etiologies. 
LEARNING ON ENCEPHALAPP
As shown in Tables 2 and 3 , there was significantly more learning with On runs in controls compared with patients with cirrhosis and in patients with cirrhosis without prior OHE compared with those with prior OHE. This was not seen during the Off stage. When explored further within the OHE group, EncephalApp On run learning effect did not differ as a function of treatment status (none, 0.63; lactulose, 2.3; rifaximin, 0.45; P 5 0.36). The recentness of the prior OHE episode did not affect the On run learning (<6 months, -0.32; 6 months to 1 year, -0.35; > 1 year, 1.02; P 5 0.49).
LONGITUDINAL FOLLOW-UP
A total of 26 cirrhotic outpatients who were a subset of the main cross-sectional cohort were retested 3 6 13 weeks apart, of whom 15 had prior OHE controlled 
BEFORE/AFTER LT
A total of 20 patients on the deceased LT list were studied before LT and 6 6 2 months after LT. These patients were stably controlled on tacrolimus after LT without episodes of rejection, sepsis, or hospitalizations within 2 months of post-LT testing. The mean age before LT was 57.2 6 6.2; 14 were men with a mean MELD at listing of 17.4 6 8.5. Twelve patients had pre-LT OHE, which was controlled on lactulose and rifaximin. There was a significant improvement in the total EncephalApp scores after LT compared with the pre-LT performance (Table 5 ). There was also a significant improvement in On runs 1-5 scores in those with prior OHE compared with their pre-LT baseline. This change was higher than that observed in patients without prior OHE.
Discussion
The study results demonstrate that cognitive flexibility, rather than psychomotor speed, is impaired There was an improvement in EncephalApp time metrics after transplant, which was largely related to improvement in those with prior OHE. These patients also improved their learning ability on the On stage of EncephalApp. *P < 0.05 before versus after LT (Wilcoxon signed rank sum test). † P < 0.05 OHE versus no-OHE (Kruskal-Wallis test).
after OHE development using the EncephalApp. The study has included 1 of the largest cohorts of cirrhotic outpatients to address the important question of whether maximally treated OHE episodes can result in lasting neurocognitive impairment. This is a relevant question because prior studies (25) have demonstrated that the persistence of impairment can lead to a severe burden on patients, caregivers, and the health care system. A prior diagnosis of OHE and cognitive impairment also modulates the extent of cognitive and brain function recovery after LT. Although the greater extent of EncephalApp impairment in patients with a prior history of OHE is to be expected, the changes in the On run, rather than the Off run, of the EncephalApp are intriguing. Although prior OHE affects both runs of the test, as was reconfirmed by our results, the individual contribution of On and Off runs toward differentiating cognitively impaired and unimpaired patients is relatively equal. Therefore, the lack of improvement, and actual deterioration over time with the On run, but not the Off runs point toward nuanced changes within the brain after OHE that cannot be picked up by simple addition of the total Off and On times.
The Stroop test, which assesses selective attention, processing speed, and in the On runs, response inhibition, has been studied in a variety of neurodegenerative disorders. (12, 13) Prior studies have demonstrated that response inhibition is impaired in patients with prior OHE by using the ICT. (4, 6) Additional studies demonstrated that this impaired learning was found over time using the PHES in HE patients. (5, 6) This is the first experience using the EncephalApp, which extends these findings into a separate, larger population with longitudinal confirmation.
The EncephalApp tests 2 separate cognitive domains within its Off and On run assessment at the same sitting. The Off run measures psychomotor speed, which is a function of cortical tone and arousal. The On run of the test examines response inhibition, which is primarily a function of lateral prefrontal cortex integrity (the development of task specific rules for the brain to perform response inhibition) and the anterior cingulate cortex (allocation of attentional resources), and it is an excellent measure of overall cognitive flexibility. The results show that Off run performance remains stable over time both within and between the patient groups regardless of the disease severity, while On run results can improve in non-OHE populations, which is intriguing. This suggests that practice effects and/or increased familiarity with the Off run trial did not benefit psychomotor speed. Level of achievement and pattern of performance remained constant for controls and patients with cirrhosis at the longitudinal follow-up and pretransplant/posttransplant analyses. Therefore, the benefit derived from task exposure is relatively equal with regard to the total times for OHE patients and patients with cirrhosis greater than no-OHE and controls, respectively. Even when exposed to the EncephalApp longitudinally, the Off time totals improved but without changes in the individual runs or learning. These findings point to a fixed ceiling for psychomotor speed, beyond which there can be little improvement.
In contrast, we found variability in On run performance between trial 1 and trial 5 that can potentially be attributed to improved response inhibition and cognitive flexibility due to increasing familiarity with the task requirements (ie, a learning effect). This was seen in healthy controls as well as in cirrhotic groups without prior OHE, but was not found in groups with prior OHE. Interestingly, repeated exposure to this test over time neither improved the total EncephalApp metrics nor the On stage learning in prior OHE patients before LT. This lack of learning was not a function of the treatments employed, etiology of cirrhosis, nor timing of the last HE episode. Therefore, the OHE patients' inability to demonstrate a learning effect from prior task stimuli exposure during the EncephalApp On runs may represent a harbinger of a dementing process in patients with cirrhosis. This poor correlation with OHE episode characteristics replicates a prior study in which the development of OHE, rather than relevant medical phenomenology was associated with poor survival. (26) Therefore, reaching the OHE stage may mark a major milestone, not only with regard to overall clinical endpoints, but perhaps also in terms of higher cortical dysfunction despite our current standard of care therapy.
It is also important to note that despite these pretransplant changes, OHE patients whose posttransplant course was stable, significantly improved on the overall EncephalApp metrics, as well as regained their capacity to learn. This is important because it reflects the potential reversibility of at least some aspects of neuropathology associated with successful transplant, despite the confounding factors of calcineurin therapy. Reversibility of this cognitive deficit after transplant is an important observation that points toward its liver-associated origin. Prior studies have shown that OHE patients have a variable outcome after transplant. (22, 27) A recent study demonstrated that a simple pretransplant OHE diagnosis was not a powerful predictor of posttransplant cognitive impairment on multimodal magnetic resonance imaging. (28, 29) Therefore, the restoration of this learning ability points toward a hopeful illness course after transplant in these patients.
Although we did not specifically examine the mechanisms accounting for changes in cognitive flexibility and response inhibition in OHE patients, prior studies have examined an altered gut-liver-brain axis with dysbiosis, sarcopenia, as well as structural and functional brain changes as contributors. (30) Indeed, in a functional magnetic resonance imaging study examining the functional basis of cognitive change after LT, Ahluwalia et al. found robust activation in areas within the dorsolateral prefrontal cortex and anterior cingulate cortex. (28) These brain regions are hypothesized to underlie successful Stroop test performance. Regardless of the specific mechanism of action, the data demonstrate that the neurobehavioral decline associated with an OHE diagnosis (ie, learning capability) is to some extent reversible. These data speak to a remarkable resiliency of brain function. Because our focus was on evaluation of OHE patients' recovery, the longitudinal studies had adequate numbers of OHE patients based on prior experiences. However, the patients without OHE may be lower than required to definitively make the conclusions longitudinally. (4, 28) However, prior data and cross-sectional analyses would not necessarily predict changes in no-OHE patients over time.
The clinical implications of these findings include recognizing the executive dysfunction in this patient population and the development of specific communication and treatment strategies to minimize their impact on patient care. For example, involving caregivers in the decision-making process, simplifying complicated dietary and medical advice, and potentially including apps or other educational tools may prove efficacious. In addition, counseling that some of these cognitive deficits may be reversible with transplant may improve treatment compliance and the patient's emotional function.
We conclude that despite current maximal treatment and normal mentation, learning, but not psychomotor speed assessed by the EncephalApp, is impaired in patients with OHE. Patients with prior OHE are able to regain their learning ability after successful LT. Clinicians should keep these learning deficits in mind when communicating with patients with OHE to potentially improve both patient care and their understanding of the disease process.
